Paper38720002
An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution.
Subissi L and 57 others. Nat Med, 2024. Cited by 24 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. Papers, record 38720002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38720002
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| SARS-CoV-2 | Major topic |
| COVID-19 | Major topic |
| Evolution, Molecular | Major topic |
| Humans |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 001 | World Health Organization | International | PubMed | PubMed | |
| 206298/Z/17/Z | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| MR/X020258/1 | Medical Research Council | United Kingdom | PubMed | PubMed | |
| ZIAAI001289 | NIH | NIH RePORTER | |||
| ZIAAI001324 | NIH | NIH RePORTER |
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35,202,601 | Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. | Lancet | 2022 | https://conductscience.org/library/papers/35202601 | PubMed |
| 2 | 35,798,890 | SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. | Nat Microbiol | 2022 | https://conductscience.org/library/papers/35798890 | PubMed |
| 3 | 34,347,959 | SARS-CoV-2 Variants in Patients with Immunosuppression. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34347959 | PubMed |
| 4 | 35,737,747 | Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. | Sci Immunol | 2022 | https://conductscience.org/library/papers/35737747 | PubMed |
| 5 | 35,104,836 | SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. | Nature | 2022 | https://conductscience.org/library/papers/35104836 | PubMed |
| 6 | 36,807,683 | When to update COVID-19 vaccine composition. | Nat Med | 2023 | https://conductscience.org/library/papers/36807683 | PubMed |
| 7 | 36,746,173 | ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. | Lancet Infect Dis | 2023 | https://conductscience.org/library/papers/36746173 | PubMed |
| 8 | 35,637,337 | An early warning system for emerging SARS-CoV-2 variants. | Nat Med | 2022 | https://conductscience.org/library/papers/35637337 | PubMed |
| 9 | 36,681,084 | Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. | Lancet Infect Dis | 2023 | https://conductscience.org/library/papers/36681084 | PubMed |
| 10 | 35,139,269 | Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35139269 | PubMed |
| 11 | 35,042,229 | Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. | Nature | 2022 | https://conductscience.org/library/papers/35042229 | PubMed |
| 12 | 36,580,913 | Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. | Cell | 2023 | https://conductscience.org/library/papers/36580913 | PubMed |
| 13 | 35,115,515 | Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. | Nat Commun | 2022 | https://conductscience.org/library/papers/35115515 | PubMed |
| 14 | 36,357,713 | Divergent SARS-CoV-2 variant emerges in white-tailed deer with deer-to-human transmission. | Nat Microbiol | 2022 | https://conductscience.org/library/papers/36357713 | PubMed |
| 15 | 38,057,313 | Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. | Nat Commun | 2023 | https://conductscience.org/library/papers/38057313 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,903,548 | Dual strategies for durable antibodies against SARS-CoV-2: Immune trajectories and viral fitness constraints. | Hlife | 2026 | https://conductscience.org/library/papers/42903548 | PubMed |
| 42,548,924 | SARS-CoV-2 NSP8-Derived Peptide Effectively Suppresses the Activity of Helicase NSP13. | Comput Struct Biotechnol J | 2026 | https://conductscience.org/library/papers/42548924 | PubMed |
| 42,174,265 | A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines. | Nat Immunol | 2026 | https://conductscience.org/library/papers/42174265 | PubMed |
| 42,034,607 | Stringent selection drives convergence toward omicron-like SARS-CoV-2 receptor-binding motifs. | Nat Commun | 2026 | https://conductscience.org/library/papers/42034607 | PubMed |
| 41,882,570 | Capturing SARS-CoV-2 immune landscapes to inform future strategies for COVID-19 vaccination in a high-income setting: a mathematical modelling study. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/41882570 | PubMed |
| 41,513,994 | Genomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/41513994 | PubMed |
| 41,450,845 | Decoding the cross-immune pressure: Dengue's role in SARS-CoV-2 evolution. | Comput Struct Biotechnol J | 2025 | https://conductscience.org/library/papers/41450845 | PubMed |
| 41,312,816 | Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study. | Influenza Other Respir Viruses | 2025 | https://conductscience.org/library/papers/41312816 | PubMed |
| 41,262,874 | Novel method for the identification of circulating SARS-CoV-2 variants and clinical characteristics of patient infection with SARS-CoV-2 variants in Central China. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41262874 | PubMed |
| 41,258,470 | A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023. | Commun Med (Lond) | 2025 | https://conductscience.org/library/papers/41258470 | PubMed |
| 41,209,021 | Distinct characteristics of T cell receptor repertoire associated with the SARS-CoV-2 reinfection. | Front Immunol | 2025 | https://conductscience.org/library/papers/41209021 | PubMed |
| 41,021,657 | Generalizing population RT-qPCR cycle threshold values-informed estimation of epidemiological dynamics: Impact of surveillance practices and pathogen variability. | PLoS Comput Biol | 2025 | https://conductscience.org/library/papers/41021657 | PubMed |
| 40,970,206 | Differential response of human plasmacytoid pre-dendritic cells to SARS-CoV-2 variants. | iScience | 2025 | https://conductscience.org/library/papers/40970206 | PubMed |
| 40,503,878 | Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies. | Microbiol Mol Biol Rev | 2025 | https://conductscience.org/library/papers/40503878 | PubMed |
| 40,391,150 | SARS-CoV-2 keeps evolving, so must our research efforts. | Natl Sci Rev | 2025 | https://conductscience.org/library/papers/40391150 | PubMed |
| 40,266,148 | Design and Characterization of Bispecific and Trispecific Antibodies Targeting SARS-CoV-2. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/40266148 | PubMed |
| 39,772,242 | A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories. | Viruses | 2024 | https://conductscience.org/library/papers/39772242 | PubMed |
| 39,587,352 | The consequences of SARS-CoV-2 within-host persistence. | Nat Rev Microbiol | 2025 | https://conductscience.org/library/papers/39587352 | PubMed |
| 39,171,921 | Interferon-stimulated genes and their antiviral activity against SARS-CoV-2. | mBio | 2024 | https://conductscience.org/library/papers/39171921 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38720002
GET https://conductscience.org/api/papers/v1/38720002/authors?page=2